Breaking News Instant updates and real-time market news.

CYTK

Cytokinetics

$9.95

0.5 (5.29%)

16:15
06/17/18
06/17
16:15
06/17/18
16:15

Cytokinetics announces data from Phase 2 clinical study of Reldesemtiv in SMA

Cytokinetics announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy, or SMA, were presented at the 2018 Annual Cure SMA Conference in Dallas. This hypothesis-generating study met its primary objective to determine potential pharmacodynamic effects of reldesemtiv after multiple oral doses in patients with SMA, and secondary objectives to evaluate the safety, tolerability and pharmacokinetics of reldesemtiv. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue. The study showed dose- and concentration-dependent increases in time to muscle fatigue as measured by changes from baseline in Six Minute Walk Distance, a sub-maximal exercise test of aerobic capacity and endurance, and Maximal Expiratory Pressure, a measure of strength of respiratory muscles, after eight weeks of treatment with reldesemtiv. The study, which examined two dose levels of reldesemtiv, 150 mg or 450 mg twice daily, demonstrated dose-dependent increases in 6MWD in ambulatory patients as measured at both post-baseline time points, week four and week eight. The study also showed increases versus placebo in MEP. Adverse events were similar between groups receiving reldesemtiv and placebo. The most commonly observed adverse effects were headache, constipation and nausea. Four patients had serious adverse events reported that resulted in early termination of study drug treatment, all considered to be unrelated to reldesemtiv.

CYTK Cytokinetics
$9.95

0.5 (5.29%)

11/22/17
11/22/17
DOWNGRADE
Target $10

Neutral
Cytokinetics downgraded after tirasemtiv discontinuation at Cantor Fitzgerald
As previously reported, Cantor Fitzgerald analyst Mara Goldstein downgraded Cytokinetics to Neutral from Overweight after the VITALITY-ALS trial failed and the company announced the discontinuation of the tirasemtiv program. While she sees opportunity for upside as clinical data emerge on omecamtiv and CK-2127107, she argues that the time to meaningful data and proximity to year-end makes a Neutral rating appropriate. Goldstein lowered her price target on Cytokinetics to $10 from $21.
11/22/17
NEED
11/22/17
DOWNGRADE
Target $12
NEED
Buy
Cytokinetics downgraded to Buy at Needham after failed tirasemtiv Phase 3
As reported earlier, Needham analyst Chad Messer downgraded Cytokinetics to Buy from Strong Buy and cut his price target to $12 from $22 after the company's Phase 3 study of tirasemtiv inamyotrophic lateral sclerosis failed to reach its efficacy endpoints. Messer says the culprit was the high dropout rates due to the tolerability issues of tirasemtiv. The analyst notes that the company will now turn its focus to developing CK-107, which has a superior tolerability profile. Messer adds that the Buy rating still reflects his expectations of potential value creation from CK-107 in FY18.
11/22/17
11/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Salesforce (CRM) downgraded to Neutral from Buy at Roth Capital with analyst Richard Baldry citing the 59% year-to-date rally in the shares. 2. Bloomin' Brands (BLMN) downgraded to Neutral from Buy at BofA/Merrill with analyst Gregory Francfort citing news of Jana Partners' 8.7% stake and subsequent share price spike. 3. Halozyme (HALO) assumed with an Equal Weight from Overweight at Barclays with analyst Gena Wang saying she believes the potential of Halozyme's Enhanze technology is largely reflected in the stock following the recent rally. 4. Mallinckrodt (MNK) downgraded to Perform from Outperform at Oppenheimer with analyst Derek Archila saying he's been "flat out wrong" on the shares. 5. Cytokinetics (CYTK) was downgraded to Neutral from Overweight at Cantor Fitzgerald and to Buy from Strong Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/19/18
HCWC
01/19/18
NO CHANGE
Target $20
HCWC
Buy
Cytokinetics price target raised to $20 from $17 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Cytokinetics to $20 after spending time with management. CK-107 could be the molecule that resets the investment thesis in 2018, Pantginis tells investors in a research note. The analyst looks for a "quick turnaround" in 2018 and keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

HWC

Hancock Whitney Corporation

$48.35

-0.1 (-0.21%)

17:03
07/17/18
07/17
17:03
07/17/18
17:03
Earnings
Hancock Whitney Corporation reports Q2 adjusted EPS 96c, consensus 95c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

MEOH

Methanex

$71.15

1.4 (2.01%)

17:03
07/17/18
07/17
17:03
07/17/18
17:03
Hot Stocks
Methanex reaches long-term pact for natural gas supply to New Zealand ops »

Methanex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$115.80

1.21 (1.06%)

17:01
07/17/18
07/17
17:01
07/17/18
17:01
Hot Stocks
Breaking Hot Stocks news story on Texas Instruments »

Texas Instruments down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

RNST

Renasant

$45.06

0.05 (0.11%)

17:01
07/17/18
07/17
17:01
07/17/18
17:01
Earnings
Renasant reports Q2 EPS 74c, consensus 74c »

"We are pleased with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$115.80

1.21 (1.06%)

16:59
07/17/18
07/17
16:59
07/17/18
16:59
Earnings
Texas Instruments reports Q2 EPS $1.40, consensus $1.31 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

DERM

Dermira

$10.57

-0.16 (-1.49%)

16:57
07/17/18
07/17
16:57
07/17/18
16:57
Hot Stocks
Breaking Hot Stocks news story on Dermira »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$72.66

0.38 (0.53%)

16:53
07/17/18
07/17
16:53
07/17/18
16:53
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United Continental up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

NLY

Annaly Capital

$10.42

0.04 (0.39%)

, MTGE

MTGE Investment

$19.70

0.05 (0.25%)

16:46
07/17/18
07/17
16:46
07/17/18
16:46
Hot Stocks
Annaly Capital extends exchange offer to acquire MTGE Investment »

Annaly Capital Management…

NLY

Annaly Capital

$10.42

0.04 (0.39%)

MTGE

MTGE Investment

$19.70

0.05 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$115.80

1.21 (1.06%)

16:42
07/17/18
07/17
16:42
07/17/18
16:42
Hot Stocks
Texas Instruments CEO Brian Crutcher resigns, Rich Templeton to succeed »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CSX

CSX

$64.42

0.46 (0.72%)

16:41
07/17/18
07/17
16:41
07/17/18
16:41
Hot Stocks
Breaking Hot Stocks news story on CSX »

CSX advances 3.2% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

WTFC

Wintrust Financial

$88.40

0.25 (0.28%)

16:40
07/17/18
07/17
16:40
07/17/18
16:40
Earnings
Wintrust Financial reports Q2 EPS $1.53, consensus $1.44 »

Edward J. Wehmer,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Sep

UBNK

United Financial

$17.40

-0.07 (-0.40%)

16:39
07/17/18
07/17
16:39
07/17/18
16:39
Earnings
United Financial reports Q2 EPS 31c, consensus 30c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

16:38
07/17/18
07/17
16:38
07/17/18
16:38
General news
API crude inventories for week of July 13 »

API reports that crude…

CASI

Casi Pharmaceuticals

$7.26

-0.215 (-2.88%)

16:38
07/17/18
07/17
16:38
07/17/18
16:38
Syndicate
Breaking Syndicate news story on Casi Pharmaceuticals »

Casi Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHAK

Shake Shack

$66.86

1 (1.52%)

16:37
07/17/18
07/17
16:37
07/17/18
16:37
Hot Stocks
Shake Shack plans to expand to Manila in spring 2019 »

Shake Shack said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 07

    Aug

  • 08

    Aug

SAH

Sonic Automotive

$20.45

0.3 (1.49%)

16:36
07/17/18
07/17
16:36
07/17/18
16:36
Hot Stocks
Breaking Hot Stocks news story on Sonic Automotive »

Sonic Automotive down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAH

Sonic Automotive

$20.45

0.3 (1.49%)

16:34
07/17/18
07/17
16:34
07/17/18
16:34
Earnings
Sonic Automotive sees Q2 adjusted cont ops EPS 32c-36c, consensus 49c »

Sonic Automotive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOPE

Hope Bancorp

$17.52

-0.05 (-0.28%)

16:32
07/17/18
07/17
16:32
07/17/18
16:32
Hot Stocks
Hope Bancorp raises quarterly dividend to 14c per share from 13c »

Hope Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 07

    Nov

NTRS

Northern Trust

$105.64

0.18 (0.17%)

16:32
07/17/18
07/17
16:32
07/17/18
16:32
Hot Stocks
Northern Trust approves new stock repurchase program of 25M shares »

Northern Trust announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CSX

CSX

$64.42

0.46 (0.72%)

16:32
07/17/18
07/17
16:32
07/17/18
16:32
Earnings
Breaking Earnings news story on CSX »

CSX expects mid-single…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

NTRS

Northern Trust

$105.64

0.18 (0.17%)

16:32
07/17/18
07/17
16:32
07/17/18
16:32
Hot Stocks
Northern Trust raises dividend 30% to 55c »

Northern Trust, holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

HOPE

Hope Bancorp

$17.52

-0.05 (-0.28%)

16:31
07/17/18
07/17
16:31
07/17/18
16:31
Earnings
Hope Bancorp reports Q2 EPS 36c, consensus 37c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 07

    Nov

FULT

Fulton Financial

$16.70

-0.05 (-0.30%)

16:31
07/17/18
07/17
16:31
07/17/18
16:31
Earnings
Fulton Financial reports Q2 EPS 20c, consensus 14c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 14

    Aug

CSX

CSX

$64.42

0.46 (0.72%)

16:31
07/17/18
07/17
16:31
07/17/18
16:31
Hot Stocks
CSX reports Q2 operating ratio 58.6% versus 67.4% in same quarter last year »

Capital investments in Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

16:30
07/17/18
07/17
16:30
07/17/18
16:30
Options
Preliminary option volume of 17.8M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.